Effectiveness of Dorzolamide–Timolol (COSOPT) in Patients Who Were Treatment Naive for Open-Angle Glaucoma or Ocular Hypertension: The COSOPT First-Line Study

Crichton, Andrew; Harasymowycz, Paul; Hutnik, Cindy; Behki, Rama; Boucher, Serge; Ibrahim, Fahim; Rifkind, Aaron W.; Solomon, Leon D.; Liao, Chuanhong; Bastien, Natacha; Sampalis, John S.

doi:10.1089/jop.2010.0032

Cited by 14 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In patients requiring treatment with more than one agent, a fixed combination therapy is usually preferred because it is associated with increased compliance 10–12. However, it has been shown that, in reality, combination therapy is often administered as first-line therapy for patients diagnosed with primary open angle glaucoma or ocular hypertension 11,13…”

Section: Introductionmentioning

confidence: 99%

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily

Moisseiev¹,

Kurtz²,

Lazar³

et al. 2013

OPTH

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to evaluate the safety and efficacy of a fixed combination of timolol maleate 0.5% + brimonidine tartrate 0.2% (Combigan®) for reduction for intraocular pressure (IOP) in patients with glaucoma when the dose frequency is increased from twice to three times daily.MethodsThe patients included had either primary open angle glaucoma or ocular hypertension. Those who were previously on treatment completed a drug washout period prior to inclusion. IOP was measured at baseline, after 4 weeks of treatment with Combigan twice daily, and again after a further 4 weeks of Combigan three times daily. Blood pressure, heart rate, and oxygen saturation were also recorded at each assessment.ResultsThirty-one eyes from 31 patients were included. Increasing the Combigan dose frequency resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.25 ± 1.18 mmHg, corresponding to a further 10.3% reduction in IOP from baseline. No local or systemic adverse effects were documented.ConclusionTreatment with Combigan three times daily was more effective in reducing IOP than the twice-daily regimen, with no increase in adverse effects.

show abstract

Section: Introductionmentioning

confidence: 99%

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily

Moisseiev¹,

Kurtz²,

Lazar³

et al. 2013

OPTH

View full text Add to dashboard Cite

show abstract

“…In patients requiring treatment with more than one agent, combination therapy is usually preferred since it is associated with increased compliance 10,11. However, it has been shown that in reality, combination therapy is often administered as first-line therapy for patients diagnosed with POAG or ocular hypertension (OHT) 11,12…”

Section: Introductionmentioning

confidence: 99%

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day

Shemesh

Moisseiev

Lazar³

et al. 2012

OPTH

View full text Add to dashboard Cite

PurposeTo evaluate the safety and efficacy in intraocular pressure (IOP) reduction of increasing Cosopt dosage from twice to three times a day.MethodsThe study included patients with primary open-angle glaucoma or ocular hypertension. After a washout period, IOP was measured at baseline, after 4 weeks of treatment with Cosopt twice a day, and after another 4 weeks of treatment with Cosopt three times a day. Blood pressure, heart rate, and oxygen saturation levels were also recorded.ResultsTwenty-nine eyes of 29 patients were included. Increasing Cosopt dosage resulted in a statistically significant (P < 0.001) additional reduction in IOP of 2.2 ± 1.58 mmHg (10.69% ± 7.49% of the baseline IOP values). There were no local or systemic adverse effects.ConclusionTreatment with Cosopt three times a day was more effective in reducing IOP than twice a day, with no effect on safety.

show abstract

“…Henderer et al 14 showed a mean percentage change of -40% in the patients after 2 months of initial treatment with Cosopt. Crichton et al 15 reported a -36.4% change in IOP after 6 weeks, and a -40.4% change in the patients treated with Cosopt after 12 weeks. Kim et al, 16 however, reported an IOP change of -23.7% at week 12 postswitch in the normal-tension glaucoma patients treated with DTFC, which was inferior to the results of the present study.…”

Section: Discussionmentioning

confidence: 96%

Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart

Hyun

Yoon

et al. 2015

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

Effectiveness of Dorzolamide–Timolol (COSOPT) in Patients Who Were Treatment Naive for Open-Angle Glaucoma or Ocular Hypertension: The COSOPT First-Line Study

Abstract: DT alone and DT in combination with a PG are effective in significantly reducing IOP in patients with untreated OAG or ocular hypertension. The treatment was safe and well tolerated with a low incidence of AEs.

Cited by 14 publications

References 35 publications

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily

Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day

Efficacy and Safety of Glaucoma Patients' Switch from a 2% Dorzolamide/0.5% Timolol Fixed-Combination Brand-Name Drug to Its Generic Counterpart

Contact Info

Product

Resources

About